Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198560 | 0.86 | CYP3A4 (0.60) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL7905176 | 0.84 | CYP3A4 (0.58) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL1180215 | 0.81 | MAPT (0.84) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL28225145 | 0.81 | CYP1A1 (0.69) | MAPTKDM4EALDH1A1RAB9ATDP1 | |
| SCHEMBL6623201 | 0.81 | MEN1 (0.46) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL12180534 | 0.80 | RAB9A (0.59) | KDM4EALDH1A1RAB9APOLBNPC1 | |
| SCHEMBL2096147 | 0.80 | MAPT (0.59) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL9830040 | 0.80 | CDC25A (0.61) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL1180096 | 0.80 | MAPT (0.59) | MAPTKDM4EALDH1A1RAB9APOLB | |
| SCHEMBL28570238 | 0.80 | KDM4E (0.62) | MAPTKDM4EALDH1A1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012141338-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-18 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
| US-4059583-A | CARDIAC RATE LOWERING | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MAPT 4299/4885KDM4E 4578/4885ALDH1A1 412/4885 |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | MAPT 3136/4885KDM4E 3416/4885ALDH1A1 109/4885 |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | MAPT 3588/4885KDM4E 4466/4885ALDH1A1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.